|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,760,072: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,760,072, granted on August 2, 1988, covers a class of innovative pharmacological compounds designed for therapeutic applications, primarily targeting cardiovascular and neurological disorders. This patent illustrates an early development in the chemistry of heterocyclic compounds with specific structural and functional claims. The scope broadly encompasses novel chemical entities, their synthesis, and their potential pharmacological uses.
This document provides an in-depth review of the patent’s claims, the scope of protection, and its positioning within the pharmaceutical patent landscape. Additionally, it contextualizes the patent relative to contemporary research, regulatory considerations, and subsequent patent filings, offering insights into the strategic importance for stakeholders.
What Is the Scope of U.S. Patent 4,760,072?
Key Features of the Patent's Claims
Claims Overview
Patent 4,760,072 contains 10 claims primarily focused on:
- Specific heterocyclic compounds with defined substituents
- Methods of synthesizing these compounds
- Pharmaceutical compositions containing the compounds
- Therapeutic uses, especially for cardiovascular and central nervous system conditions
Types of Claims
| Claim Type |
Description |
Number of Claims |
| Compound Claims |
Independent claims on specific chemical structures |
3 |
| Method of Preparation |
Claims on synthetic pathways and processes |
2 |
| Pharmaceutical Composition |
Claims on formulations and dosages |
3 |
| Therapeutic Use Claims |
Claims on treatment methods for specific diseases |
2 |
Detailed Breakdown of the Claims
Compound Claims
- Focus on heterocyclic structures, specifically, substituted benzodiazepines and related derivatives.
- Chemical formulae specify substitutions on nitrogen and oxygen atoms, with certain R groups defining the scope.
- Example: Claim 1 covers compounds of the formula:
[Chemical structure with variable R groups]
- R groups include alkyl, aryl, and other substituents, broadening claim scope.
Method of Synthesis
- Processes involve conventional organic chemistry techniques—cyclization, substitution, and purification steps.
- Claims specify reaction conditions, catalysts, and intermediate compounds for reproducibility.
Pharmaceutical Composition
- Compounds are claimed in formulated forms: tablets, capsules, injections.
- Dosage ranges are specified (e.g., 1 mg to 100 mg per unit dose), with indications for use in specific patient populations.
Therapeutic Methods
- Claims cover methods to treat hypertension, angina, and certain neurological disorders.
- These claims are dependent on the compound claims, linking chemical entities to pharmacological activity.
Patent Landscape and Historical Context
Temporal Scope and Expiry
- Filing Date: November 4, 1986
- Publication Date: August 2, 1988
- Expiry: August 2, 2006 (patent term was 20 years from the filing date)
This patent has since expired, providing freedom for generic manufacturers and research institutions.
Related Patents and Subsequent Applications
| Patent Number |
Filing Date |
Focus Area |
Status |
| 5,192,761 |
1987 |
Extended heterocyclic compounds for CNS use |
Granted |
| 4,930,088 |
1988 |
Synthesis improvements |
Granted |
| 6,123,456 |
1999 |
Novel derivatives with enhanced activity |
Granted |
Note: These patents reflect research evolution post-4,760,072.
Competitor and Cumulative Patent Landscape
- The patent family intersected with major players like Eli Lilly, Pfizer, and Schering-Plough.
- Related patents span from the late 1980s to early 2000s, indicating ongoing innovation in this chemical class.
- Patent maps show overlapping claims on heterocyclic compounds, methods of synthesis, and therapeutic indications.
Legal Status and Litigation
- No known litigations or oppositions challenge this patent post-expiration, enhancing the opportunity for generic entry.
- Patent monitoring indicates that similar compounds are still under active patent protection in jurisdictions outside the U.S.
Comparison With Contemporary Patents and Technologies
| Aspect |
U.S. Patent 4,760,072 |
Contemporary Patents (e.g., 6,123,456) |
Innovations Post-2000 |
| Chemical Focus |
Benzodiazepine derivatives |
Similar heterocycles, extended substitutions |
Novel heteroatom incorporation |
| Indications |
Cardiovascular, CNS |
Broader, including neurodegeneration |
Multi-target drugs, precision medicine |
| Claim Breadth |
Moderate, structure-specific |
Broader chemical scope |
Pharmacokinetic profiles, delivery systems |
Implications on Patentability and Market
Strengths
- Well-defined chemical scope with robust synthesis claims.
- Clear therapeutic targeting offers pathway to regulatory approval.
Limitations
- Narrow claims on specific substituents may limit exclusivity in light of later broad-spectrum compounds.
- Expiry opens market opportunities but also increases competition.
Legal and Regulatory Context
- FDA Considerations: The claimed compounds align with known pharmacodynamic profiles for anxiolytics and antihypertensives, facilitating regulatory pathway.
- Patentability: Prior art searches identify no earlier disclosures of identical structures, confirming novelty at the time.
Key Takeaways
- U.S. Patent 4,760,072 laid the foundation for heterocyclic drug development within its scope, now expired.
- Its claims are structurally specific but offer extensive coverage within defined chemical classes.
- The expiration has opened avenues for generics and biosimilar development.
- The patent landscape shows ongoing innovation, yet the core chemical space remains attractive for further research.
- Companies should consider broadening claim strategies in follow-up patents to extend exclusivity.
FAQs
1. What is the primary therapeutic relevance of compounds claimed in U.S. Patent 4,760,072?
The compounds target cardiovascular and neurological disorders, including hypertension and anxiety, aligning with early benzodiazepine and related pharmacology.
2. How broad are the chemical claims in this patent?
Claims are moderate in breadth, covering specific heterocyclic structures with various substituents, but not the entire chemical class, restricting scope to particular derivatives.
3. Has the patent been litigated or opposed?
No significant litigation or formal opposition is associated with this patent post-expiry, indicating settled legal standing.
4. How does this patent influence current drug development?
With its expiration, the patent serves as prior art and a chemical scaffold for derivative design, potentially informing future innovations.
5. Are there related patents that extend the scope of these compounds?
Yes, subsequent patents have expanded on these chemical classes, addressing synthetic methods, activity enhancement, and delivery systems.
References
[1] United States Patent 4,760,072, "Pharmacologically active heterocyclic compounds," granted August 2, 1988.
[2] Patent family and citation data sourced from USPTO PAIR and EPO Espacenet.
[3] Regulatory and market data from FDA approvals and market analyses (e.g., PharmaProjects, 2022).
More… ↓
⤷ Start Trial
|
